美国 · SEC FORM 4
Assertio Holdings, Inc.
ASRT · — · CIK 0001808665 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
16 同一窗口内观察到的 Form 4 交易行
0 sales · 16 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-11-18 · Mason Heather L.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- —
- 3M
- —
- 6M
- —
- 12M
- —
波动率与流动性
- 波动率
- —
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- -25.6%
- ROE
- -32.3%
- 细分行业
- Pharmaceutical Preparations
市场数据
价格数据截至:2026-10-08 · 价格来源:OpenBB/yfinance · 来自 SEC 申报文件:利润率, ROE · 财年截止日:2025-12-31 · Status: PASS
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-11-18 | Mason Heather L | 买入 (P) | Common Stock | 75,000 | USD 0.80 | USD 60,000 | SEC 申报 ↗ |
| 2024-11-14 | O'Grady Brendan P. | 买入 (P) | Common Stock | 11,706 | USD 0.85 | USD 9,950 | SEC 申报 ↗ |
| 2024-06-11 | Vacirca Jeff L | 买入 (P) | Common Stock | 10,000 | USD 1.11 | USD 11,100 | SEC 申报 ↗ |
| 2024-06-05 | Mason Heather L | 买入 (P) | Common Stock | 25,000 | USD 0.97 | USD 24,250 | SEC 申报 ↗ |
| 2021-05-20 | Schwichtenberg Paul | 买入 (P) | Common Stock | 9,750 | USD 1.51 | USD 14,722 | SEC 申报 ↗ |
| 2021-05-20 | Peisert Daniel A. | 买入 (P) | Common Stock | 15,909 | USD 1.54 | USD 24,500 | SEC 申报 ↗ |
| 2021-05-20 | Patel Ajay | 买入 (P) | Common Stock | 8,170 | USD 1.53 | USD 12,500 | SEC 申报 ↗ |
Form 4 申报证据
35 transaction lines in the latest 365-day window; 231 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Stark David Matthew | U (U) | Common Stock | 11,420 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Schwichtenberg Paul | U (U) | Common Stock | 13,987 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Schlessinger Sam | U (U) | Common Stock | 14,738 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Stark David Matthew | U (U) | Common Stock | 11,420 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Schwichtenberg Paul | U (U) | Common Stock | 13,987 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Schlessinger Sam | U (U) | Common Stock | 14,738 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Reisenauer Mark L | U (U) | Common Stock | 3,583 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Patel Ajay | U (U) | Common Stock | 15,942 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Mason Heather L | U (U) | Common Stock | 27,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | MCKEE WILLIAM | U (U) | Common Stock | 27,936 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Kirk Sigurd | U (U) | Common Stock | 12,017 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Emany Sravan Kumar | U (U) | Common Stock | 23,855 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Mason Heather L | 赠与 (G) | Common Stock | 6,666 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | Stark David Matthew | 奖励/授予 (A) | Common Stock | 4,851 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | Mason Heather L | 奖励/授予 (A) | Common Stock | 4,851 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | MCKEE WILLIAM | 奖励/授予 (A) | Common Stock | 4,851 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | Kirk Sigurd | 奖励/授予 (A) | Common Stock | 4,851 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | Emany Sravan Kumar | 奖励/授予 (A) | Common Stock | 4,851 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-21 | Schwichtenberg Paul | 期权行权/转换 (M) | Common Stock | 1,143 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-21 | Schwichtenberg Paul | 代扣税 (F) | Common Stock | 566 | USD 11.84 | USD 6,701 | SEC 申报 ↗ |
| 2026-02-21 | Schlessinger Sam | 期权行权/转换 (M) | Common Stock | 1,143 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-21 | Schlessinger Sam | 代扣税 (F) | Common Stock | 510 | USD 11.84 | USD 6,038 | SEC 申报 ↗ |
| 2026-02-21 | Patel Ajay | 期权行权/转换 (M) | Common Stock | 1,143 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-21 | Patel Ajay | 代扣税 (F) | Common Stock | 566 | USD 11.84 | USD 6,701 | SEC 申报 ↗ |
| 2026-02-18 | Schwichtenberg Paul | 期权行权/转换 (M) | Common Stock | 2,778 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-18 | Schwichtenberg Paul | 代扣税 (F) | Common Stock | 1,377 | USD 11.87 | USD 16,345 | SEC 申报 ↗ |
| 2026-02-18 | Schlessinger Sam | 期权行权/转换 (M) | Common Stock | 2,778 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-18 | Schlessinger Sam | 代扣税 (F) | Common Stock | 1,239 | USD 11.87 | USD 14,707 | SEC 申报 ↗ |
| 2026-02-18 | Patel Ajay | 期权行权/转换 (M) | Common Stock | 2,778 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-18 | Patel Ajay | 代扣税 (F) | Common Stock | 1,377 | USD 11.87 | USD 16,345 | SEC 申报 ↗ |
| 2026-02-07 | Schwichtenberg Paul | 期权行权/转换 (M) | Common Stock | 1,666 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-07 | Schwichtenberg Paul | 代扣税 (F) | Common Stock | 825 | USD 12.74 | USD 10,510 | SEC 申报 ↗ |
| 2026-02-07 | Schlessinger Sam | 期权行权/转换 (M) | Common Stock | 1,389 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ASRT |
| CIK | 0001808665 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 231 transaction lines from 2020-05-19 to 2026-06-16 7 P purchase lines · 19 S sale lines · 205 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.